LASIX TABLET 40 mg

国: シンガポール

言語: 英語

ソース: HSA (Health Sciences Authority)

有効成分:

FUROSEMIDE

から入手可能:

SANOFI-AVENTIS SINGAPORE PTE. LTD.

ATCコード:

C03CA01

投薬量:

40.00 mg

医薬品形態:

TABLET

構図:

FUROSEMIDE 40.00 mg

投与経路:

ORAL

処方タイプ:

Prescription Only

製:

Opella Healthcare International SAS

認証ステータス:

ACTIVE

承認日:

1988-03-28

情報リーフレット

 
This package insert is continually
updated: please read carefully before using a new pack! 

LASIX® 
_Active ingredient: Furosemide_ 
[Sanofi logo] 
Tablet 
COMPOSITION 
Each tablet contains, as active ingredient, 40 mg furosemide. 
Excipients: Maize starch, pregelatinized maize starch,
lactose, colloidal anhydrous silica, talc, 
magnesium stearate. 

PROPERTIES 
Lasix is a medicine which increases urine excretion (loop
diuretic) and lowers high blood 
pressure (antihypertensive). 

INDICATIONS 
Oedema due to cardiac, hepatic, or renal disorders (in the
presence of nephrotic syndrome, 
treatment of the basic disorder is the prime concern). Oedema due
to burns. Mild to moderate 
hypertension. 

CONTRAINDICATIONS 
Lasix must not be used in patients with: 
– renal failure accompanied by lack of urine formation (anuria)
in patients not responding to 
furosemide 
– hepatic coma and precoma 
– severely reduced blood levels of
potassium (hypokalaemia), or of sodium (hyponatraemia) 
– decreased volume of blood in the body (hypovolaemia) –
with or without reduced blood 
pressure (hypotension) – or dehydration 
– hypersensitivity to furosemide or any of the
excipients (see “Composition”). Patients allergic 
to sulphonamides (e.g. sulphonamide
antibiotics or sulphonylureas) may show cross-
sensitivity to furosemide. 
–- lactation 

_PREGNANCY AND LACTATION _
Furosemide crosses the placental barrier. Therefore, Lasix
must not be given during 
pregnancy unless there are compelling medical reasons. If
Lasix is given during pregnancy, 
fetal growth must be monitored. 
Furosemide passes into breast milk and inhibits lactation. Therefore,
Lasix must not be used 
during breast-feeding. 

SPECIAL WARNINGS AND PRECAUTIONS 
During treatment with Lasix, output of urine
must be secured. Patients whose outflow is 
obstru

製品の特徴

SG/LAS/0823/CCDS13
LASIX®
_Active ingredient: Furosemide _
Tablet
COMPOSITION
Each tablet contains, as active ingredient, 40 mg furosemide.
Excipients: Maize starch, pregelatinized maize starch, lactose
monohydrate, colloidal anhydrous
silica, talc, magnesium stearate.
PROPERTIES
Lasix is a medicine which increases urine excretion (loop diuretic)
and lowers high blood
pressure (antihypertensive).
INDICATIONS
Oedema due to cardiac, hepatic, or renal disorders (in the presence of
nephrotic syndrome,
treatment of the basic disorder is the prime concern). Oedema due to
burns. Mild to moderate
hypertension.
CONTRAINDICATIONS
Lasix must not be used in patients with:
–
hypersensitivity to furosemide, sulfonamides (possible cross
sensitivity with furosemide) or
to any of the excipients
–
renal failure with anuria refractory to furosemide therapy
–
hepatic coma and precoma associated with hepatic encephalopathy
–
severe hypokalaemia – see Adverse Reaction
–
severe hyponatraemia
–
decreased volume of blood in the body (hypovolaemia) – with or
without reduced blood
pressure (hypotension) – or dehydration
–
breast-feeding mothers
_FERTILITY, PREGNANCY AND LACTATION _
Pregnancy
Furosemide should only be used in pregnancy for short periods and
after the need to treat is
carefully weighed as it crosses the placental barrier.
Diuretics are not suitable for the routine treatment of hypertension
and oedema in pregnancy,
since they impair placental perfusion and thereby intrauterine growth.
However, if furosemide has to be given in maternal heart failure or
renal insufficiency, electrolytes
and haematocrit as well as the foetal growth must be closely
monitored. Displacement of
bilirubin from the albumin binding site, resulting in an increased
risk of kernicterus in
hyperbilirubinaemia, has been described for furosemide.
Furosemide crosses the placental barrier and reaches 100% of maternal
serum concentration in
cord blood. No malformations in humans that could be associated with
exposure to furosemide
have been